Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk ( SUSTAIN 6)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk ( SUSTAIN 6)

Published:2020-04-27 Issue:8 Volume:22 Page:1339-1347
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Jódar Esteban¹²^ORCID,Michelsen Marie³,Polonsky William⁴⁵,Réa Rosangela⁶,Sandberg Anna³,Vilsbøll Tina⁷^ORCID,Warren Mark⁸^ORCID,Harring Signe³,Ziegler Uwe³,Bain Stephen⁹^ORCID

Affiliation:

1. Faculty of MedicineUniversidad Europea de Madrid Madrid Spain

2. Department of Endocrinology and Nutrition ServiceHospital Universitario QuironSalud Madrid Madrid Spain

3. Novo Nordisk A/S Søborg Denmark

4. Behavioral Diabetes Institute San Diego, California

5. Department of PsychiatryUniversity of California San Diego La Jolla, California

6. Department of Clinical MedicineSEMPR, Universidade Federal do Paraná Curitiba Brazil

7. Steno Diabetes Center CopenhagenUniversity of Copenhagen Hellerup Denmark

8. Department of EndocrinologyPhysicians East Greenville, North Carolina

9. Diabetes Research Unit CymruSwansea University Medical School Swansea UK

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14039

Reference37 articles.

1. Health-Related Quality of Life Measurement in Type 2 Diabetes

2. Quality of life and depression of people living with type 2 diabetes mellitus and those at low and high risk for type 2 diabetes: findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD)

3. Change in health status (EQ-5D) over 5 years among individuals with and without type 2 diabetes mellitus in the SHIELD longitudinal study

4. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

5. Not all roads lead to Rome-a review of quality of life measurement in adults with diabetes

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological interventions in human aging;Ageing Research Reviews;2024-03

2. Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond;Metabolism;2024-02

3. Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE);Diabetes Care;2024-01-08

4. Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study;Diabetes Research and Clinical Practice;2023-12

5. Letter to the Editor: Comment on Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons;Facial Plastic Surgery;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3